Rapid and sustained relief from the symptoms of carcinoid syndrome : results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide

• This 6-month, open, non-controlled, multicenter, dose-titration study evaluated the efficacy and safety of 28-day prolonged-release (PR) lanreotide in the treatment of carcinoid syndrome. Eligible patients had a carcinoid tumor with > or =3 stools/day and/or > or =1 moderate/severe flushing episodes/day. Six treatments of 28-day PR lanreotide were administered by deep subcutaneous injection. The dose for the first two injections was 90 mg. Subsequent doses could be titrated (60, 90, 120 mg) according to symptom response. Seventy-one patients were treated. Flushing decreased from a mean of 3.0 at baseline to 2.3 on day 1, and 2.0 on day 2, with a daily mean of 2.1 for the first week post-treatment (p < 0.05). Diarrhea decreased from a mean of 5.0 at baseline to 4.3 on day 1 (p < 0.05), and 4.5 on day 2, with a daily mean of 4.4 for the first week post-treatment (p < 0.001). Symptom frequency decreased further after the second and third injections, and reached a plateau after the fourth injection. By month 6, flushing and diarrhea had significantly decreased from baseline by a mean of 1.3 and 1.1 episodes/day, respectively (both p < or = 0.001); 65% of patients with flushing as the target symptom and 18% of diarrhea-target patients achieved > or =50% reduction from baseline. Median urinary 5-hydroxyindoleacetic acid and chromogranin A levels decreased by 24 and 38%, respectively. Treatment was well tolerated. 28-day PR lanreotide was effective in reducing the symptoms and biochemical markers associated with carcinoid syndrome.

Keyword

Adult

Aged

Aged; 80 and over

Chromogranins/blood

Comparative Study

Delayed-Action Preparations/*therapeutic use

Dose-Response Relationship; Drug

Drug Administration Schedule

Drug Evaluation/methods

Female

Flushing/drug therapy/physiopathology

Humans

Hydroxyindoleacetic Acid/urine

Male

Malignant Carcinoid Syndrome/complications/*drug therapy/metabolism

Middle Aged

Peptides; Cyclic/blood/*therapeutic use

Quality of Life

Research Support; Non-U.S. Gov't

Somatostatin/*analogs & derivatives/blood/*therapeutic use

Time Factors

Treatment Outcome

Vipoma/drug therapy/physiopathology

MEDICINE

MEDICIN

Publication and Content Type

vet (subject category)

art (subject category)